HSD17B12 and neoplasm: Among dMMR CRC patients who were pathologically classified as tumor regression grade 2 (TRG2) after immunotherapy, HSD17B12 expression was significantly lower compared to the broader nonimmunotherapy CRC cohort (Fig 1H,1I).